Patent ID: 11896596
Assignee: BEIGENE SWITZERLAND GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 8:
9. A method of treating or delaying progression of a B-cell proliferative disorder in a patient, the method comprising
selecting the patient who is being treated with a moderate CYP3A inducer; and
concomitantly administering to the selected patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 320 mg twice a day, and the moderate CYP3A inducer,
wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL).